Demonstrating the cellular activity of novel small molecule inhibitors and that their pharmacology is consistent with the expected target inhibition is critical to progressing novel therapeutics. Key techniques include high content imaging, flow cytometry, cell-based reporter assays (e.g. BiBiT™), ELISA, high throughput western blot, in-cell target engagement, RNAseq, and cell growth/cytotoxicity. These techniques support project mechanism of action studies, biomarker identification, and in vitro–in vivo translation studies. We have extensive experience of progressing small molecules for oncology indications from hit ID to early pre-clinical development including managing in vivo studies with external providers.
